Clinical Trial Update: Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Yttrium-90 radioembolization combined with durvalumab, gemcitabine, and cisplatin for intrahepatic cholangiocarcinoma. The stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Durvalumab (durvalumab)
• Gemcitabine (Gemcitabine)
• Yttrium-90 (yttrium-90)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Bile Duct Cancer, Cholangiocarcinoma | Phase 2 | Status: RECRUITING